Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Biodesix, Bruker launch agreement to support lung cancer test
May 2013
SHARING OPTIONS:

BOULDER, Colo.Biodesix Inc. and Bruker Daltonics have come together in a collaborative agreement to support Biodesix's VeriStrat diagnostic test and future diagnostic tests based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The agreement establishes precedents for hardware, software and applications support in addition to access to the latest instrument designs and improvements. Financial details were not released. VeriStrat is a novel, multivariate serum protein test that aids oncologists in personalizing therapy for lung cancer patients.
 
"We are pleased to solidify our relationship with one of our key partners with this new agreement. The support we receive from Bruker will substantially benefit both the delivery and development of our diagnostic tests," Dr. Gary Pestano, head of Product Development and Lab Operations at Biodesix, said in a statement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.